ViGenCell (308080.KQ) Akcie Kurz

ViGenCell, Inc. engages in the research and development of natural science and engineering. The company is headquartered in Seoul, Seoul and currently employs 80 full-time employees. The company went IPO on 2021-08-25. The firm is engaged in the development and manufacture of immuno-cancer cell therapy products and immunosuppressive cell therapy products. In addition, the Company is engaged in the provision of vitier platform as an antigen-specific killing t cell treatment, viranger platform as a gammadelta t cell gene therapy and vimedier platform-based technology as a myeloid suppressor cell therapy derived from umbilical cord blood. The company is engaged in the research and development of new drugs such as acute myeloid leukemia (AML) and glioblastoma.